Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Diseases of the Esophagus

Camrelizumab, Paclitaxel and Nedaplatin as Conversion Therapy for Locally Advanced/Advanced Esophageal Squamous Cell Carcinoma: A Phase Ii, Single-Arm Study

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJianqun MaYYYingnan YangJZJinfeng Zhang

Discussion

Loading...

Member takes

Overview

Phase II study shows improved overall survival and conversion therapy outcomes in unresectable ESCC, suggesting possible predictive models based on tumor radiomics.

Key Points

  • The study reveals a 56.7% objective response rate for patients with unresectable esophageal squamous cell carcinoma, indicating good efficacy.
  • Among the patients treated, the surgical conversion rate was found to be 48.9%, enhancing the potential for surgical resection.
  • Utilizing a model that combines habitat radiomics data with clinical variables, the study effectively predicts pathological complete response rates.
  • Adverse events were reported in 75.9% of patients, suggesting that while the therapy is promising, monitoring for side effects is important.

Cite This Study

Ma et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478b8e4https://doi.org/10.1093/dote/doaf061.043
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1287. CAMRELIZUMAB, PACLITAXEL AND NEDAPLATIN AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESPRIT): A PHASE II, SINGLE-ARM STUDY2025
  2. 2223. CAMRELIZUMAB AND CHEMOTHERAPY AS NEOADJUVANT TREATMENT FOR LOCALLYADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)A SINGLE-ARM, PHASE II TRIAL2025
  3. 3Analysis of camrelizumab in neoadjuvant chemotherapy for esophageal cancer: A retrospective cohort study2025 · 4 citations
  4. 4236. SAFETY AND EFFICACY OF CAMRELIZUMAB COMBINED WITH RADIOTHERAPY AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025
  5. 5024. CONVERSION ESOPHAGECTOMY FOLLOWING IMMUNOCHEMOTHERAPY IN UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A SINGLE-CENTER, PROSPECTIVE STUDY2025